請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28329完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 余家利 | |
| dc.contributor.author | Wei-Bo Liu | en |
| dc.contributor.author | 劉韋博 | zh_TW |
| dc.date.accessioned | 2021-06-13T00:05:19Z | - |
| dc.date.available | 2007-08-08 | |
| dc.date.copyright | 2007-08-08 | |
| dc.date.issued | 2007 | |
| dc.date.submitted | 2007-07-30 | |
| dc.identifier.citation | 1. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7
2. Slack JL, Schooley K, Bonnert TP, Mitcham JL, Qwarnstrom EE, Sims JE,Dower SK. Identification of two major sites in the type Iinterleukin-1 receptor Cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways. J Biol Chem 2000; 275:4670–4678 3. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, Segal DM. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 2003; 24:528-33. 4. Nurnberger T, Brunner F. Innate immunity in plants and animals: emerging parallels between the recognition of general elicitors and pathogen-associated molecular patterns. Curr Opin Plant Biol 2002; 5:318–324. 5. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-76. 6. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A.The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999; 401: 811–815. 7. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double- stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-8. 8. Miyake K. Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2.Int Immunopharmacol.2003; 3:119-28. 9. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099-103. 10. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5. 11. Sandor F, Buc M. Toll-like receptors. II. Distribution and pathways involved in TLR signalling.Folia Biol 2005; 51:188-97. 12. AkiraS, TakedaK. Toll-like receptor signaling. Nature reviews immunology 2004; 4:499-511. 13. Blander J M, Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 2004; 304:1014-1018. 14. Thoma-Uszynski S, Stenger S, Takeuchi O, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291:1544-1547. 15. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses.Nature Immunol 2004;5:987-95. 16. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity.Micro.bes Infect 2004;6:1382-7 17. Yrlid U, Milling SW, Miller JL, Cartland S, Jenkins CD, MacPherson GG. Regulation of intestinal dendritic cell migration and activation by plasmacytoid dendritic cells, TNF-alpha and type 1 IFNs after feeding a TLR7/8 ligand. J Immunol 2006; 176:5205-12. 18. Dabbagh K,Lewis DB.Toll-like receptors and T-helper-1/T-helper-2 responses.Curr Opin Infect Dis 2003; 16:199-204 19. Akira S.Toll-like receptors: lessons from knockout mice.Biochem Soc Trans 2000; 28:551-6. 20. Jankovic D, Kullberg MC, Hieny S, Caspar P, Collazo CM, Sher A. In the absence of IL-12, CD4(+) T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10(-/-) setting.Immunity 2002; 16:429-39 21. Sieling PA, Chung W, Duong BT, Godowski PJ, Modlin RL.Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J Immunol 2003;170:194–200. 22. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by b-defensin 2. Science 2002; 298:1025–1029. 23.Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, Ozaki Y, Tomizawa H, Akira S, Fukuhara S. Interferon-a and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195:1507–1512 24. Ichikawa HT, Williams LP, Segal BM. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J Immunol 2002; 169:2781–2787. 25. Eisenbarth SC, Piggott DA, Huleatt JW, et al. Lipopolysaccharide-enhanced, Toll-Like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002; 196:1645–1651. 26. Kaisho T, Hoshino K, Iwabe T, et al. Endotoxin can induce MyD88-deficient dendritic cells to support T(h)2 cell differentiation. Int Immunol.2002; 14:695-700. 27. Dabbagh K, Dahl ME, Stepick-Biek P, Lewis DB. Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells.J Immunol 2002; 168:4524–4530. 28. Masuda A, Yoshikai Y, Aiba K, Matsuguchi T. Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-Jun N-terminal kinase and p38 pathways. J Immunol 2002; 169: 3801–3810. 29. Liu N, Ohnishi N, Ni L, et al. CpG directly induces T bet expression and inhibits IgG1 and IgE switching in B cells.Nat Immunol 2003; 4:687-693. 30. Pasare C. and Medzhitov, R. Control of B-cell responses by Toll-like receptors. Nature 2005; 438:364-368. 31. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006; 36:810-6. 32. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-6. 33. Haiying Liu, Mousa Komai-Koma, Damo Xu, and Foo Y. Liew. Toll-like receptor 2 signaling modulates the functions of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006; 103:7048-7053. 34. Duez C, Gosset P, Tonnel AB. Dendritic cells and toll-like receptors in allergy and asthma.Eur J Dermatol 2006; 16:12-6. 35. Homma T, Kato A, Hashimoto N, Batchelor J, Yoshikawa M, Imai S, Wakiguchi H, Saito H,Matsumoto K. Corticosteroid and cytokines synergistically enhance toll- like receptor 2 expression in respiratory epithelial cells. Am J Respir Cell Mol Biol 2004; 31:463-9. 36. Yang IA, Fong KM, Holgate ST, Holloway JW. The role of Toll-like receptors and related receptors of the innate immune system in asthma.Curr Opin Allergy Clin Immunol 2006; 6:23-8. 37. Rifkin, I. R., Leadbetter, E. A., Busconi, L., Viglianti, G.& Marshak-Rothstein, A. Toll-like receptors,endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005; 204:27–42. 38. Busconi L,Lau CM,Tabor AS,Uccellini MB,Ruhe Z,Akira S, Viglianti GA, Rifkin. IR,Marshak-Rothstein A.DNA and RNA autoantigens as autoadjuvants.J Endotoxin Res 2006; 12:379-84. 39. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease.Nat Rev Immunol 2006; 6:823-35. 40. Means TK,Latz E,Hayashi F,Murali MR,Golenbock DT,Luster AD.Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest 2005; 115:407–417. 41. Vollmer, J. et al. Autoantigen binding sites within small nuclear RNAs induce innate immunity through Toll-like receptors 7 and 8. J Exp Med 2005; 202: 1575–1585 42. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH, Sonderegger I, Bachmaier K, Kopf M, Penninger JM.Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003; 9:1484-90. 43. Kerfoot SM, Long EM, Hickey MJ, Andonegui G, Lapointe BM, Zanardo RC, Bonder C, James WG, Robbins SM, Kubes P.TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J. Immunol 2004; 173:7070–7077. 44. Joosten LA,Koenders MI,Smeets RL,Heuvelmans-Jacobs M,Helsen MM,Takeda K,Akira S,Lubberts E,van de Loo FA,van den Berg WB. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003; 171:6145-53. 45. Lang KS,Recher M,Junt T,Navarini AA,Harris NL,Freigang S,Odermatt B,Conrad C,Ittner LM,Bauer S,Luther SA,Uematsu S,Akira S,Hengartner H,Zinkernagel RM.Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nature Med 2005; 11:138–145 . 46.Childs SG.The pathogenesis of systemic lupus erythematosus.Orthop Nurs 2006;25:140-5 47. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725 48. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus.J Clin Pathol 2003; 56:481-90. 49. Nagy G, Barcza M, Gonchoroff N, Phillips PE, Perl A.Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol 2004; 173:3676-83. 50. Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA.Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).J Immunol 1983; 130:2651-5. 51. Tao D, Shangwu L, Qun W, Yan L, Wei J, Junyan L, Feili G, Boquan J,Jinquan T.CD226 expression deficiency causes high sensitivity to apoptosis in NK T cells from patients with systemic lupus erythematosus. J Immunol 2005;174:1281-90. 52. Kyttaris VC,Juang YT,Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: an update.Curr Opin Rheumatol 2005; 17:518-22. 53. Grossman JM, Kalunian KC.Definition, classfication, activity, and damage indics.In:Wallace DJ, Hahn BH, eds. Sixth edition.Dubois’Lupus Erythematosus.Philadelphia: Lippincott Willians & Wilkins 2002; 19-31. 54. Ioannou Y, Isenberg DA. Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge.Postgrad Med J 2002;78:599-606. 55. Urowitz MB, Gladman DD. Evolving spectrum of mortality and morbidity in SLE Lupus 1999; 8:253–5. 56. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982; 216:429–431. 57. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004; 20:539–550. 58. Wang Y, Krieg AM.Synergy between CpGor non-CpG DNA and specific antigen for B cell activation. Int Immunol 2003; 15: 223–231. 59. Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNFalpha, p55 srTNFalpha, p75 srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999;18:17–22. 60. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4:393–5. 61. Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus.I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine 1998; 10:140–7. 62. Hamann L, Hamprecht A, Gomma A, Schumann RR.Rapid and inexpensive real-time PCR for genotyping functional polymorphisms within the Toll-like receptor -2, -4, and -9 genes. J Immunol Methods.2004; 285:281-91. 63. Sanchez E, Orozco G, Lopez-Nevot MA, Jimenez-Alonso J, Martin J. Polymorphisms of toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus.Tissue Antigens 2004; 63:54-7. 64. Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsuhashi H, Kimura H, Ishibashi H, Eguchi K.Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 2007; 34:493-500. 65. Hailman E, Vasselon T, Kelley M, Busse LA, Hu MC, Lichenstein HS, Detmers PA, Wright SD.Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J Immunol 1996; 156:4384–4390. 66. Pugin J, Schürer-Maly C-C, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS.Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA 1993; 90:2744–2748. 67. Kitchens RL, Thompson PA, Viriyakosol S, O’Keefe GE,Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001; 108:485–493. 68. Stelter F, Witt S, Fürll B, Jack RS, Hartung T, Schütt C. Different efficacy of soluble CD14 treatment in high- and low-dose LPS models. Eur J Clin Invest 1998; 28: 205–213. 69. LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M, Griffin GE, Ferrara P, Schiffrin EJ, Morgan BP, Labeta MO. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk.J Immunol 2003; 171:6680-9. 70. Kuroishi T, Tanaka Y, Sakai A, Sugawara Y, Komine K, Sugawara S.Human parotid saliva contains soluble toll-like receptor (TLR) 2 and modulates TLR2-mediated interleukin-8 production by monocytic cells.Mol Immunol 2007; 44:1969-76. 71. Ueland T, Espevik T, Kjekshus J, Gullestad L, Omland T, Squire IB, Froland SS, Mollnes TE, Dickstein K, Aukrust P. Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction.J Card Fail 2006; 12:659-63. 72. Mudd PA, Teague BN, Farris AD.Regulatory T cells and systemic lupus erythematosus.Scand J Immunol 2006;64:211-8. 73. Roger P.M. Sutmuller, Martijn H.M.G.M. den Brok, Matthijs Kramer, Erik J. Bennink, Liza W.J.Toonen, Bart-Jan Kullberg, Leo A. Joosten, Shizuo Akira, Mihai G. Netea, and Gosse J. Adema1. Toll-like receptor 2 controls expansion and function of regulatory T cells. JCI 2006; 16:485-494. 74. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors.Biochim Biophys Acta 2002; 1589:1-13. 75. Goldblatt F, Isenberg DA.New therapies for systemic lupus erythematosus. Clin. Exp.Immunol 2005; 140:205-12. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28329 | - |
| dc.description.abstract | 近年來發現的模式辨識受體(pattern recognition receptors)家族中，Toll-like受體(TLRs)在脊椎動物先天與後天免疫的調節活化上，扮演著相當重要的角色。TLRs可表現在許多不同的細胞及組織上，其中包含樹突細胞、巨噬細胞及顆粒球細胞，主要為辨識革蘭氏陽性與陰性細菌、病毒的RNA、非甲基化CpG DNA、及黴菌等病原分子。研究顯示，TLRs從多個途徑影響生物體的免疫反應，與慢性炎症疾病及系統性自體免疫疾病發展有著密切的關係。全身性紅斑狼瘡(systemic lupus erythematosus, SLE)為全身性的自體免疫疾病，其致病機轉至今尚未完全清楚；本實驗我們透過正常人與SLE病人多形核嗜中性白血球(PMN)與單核性細胞(MNC)上TLR2及TLR4表現量的差異與否，進一步了解是否有其他協同作用分子也參與TLR2及TLR4訊息傳導，藉此找出與SLE疾病相關的TLRs訊息傳遞機轉。
實驗結果發現，TLR2及TLR4在正常人與SLE病人PMN和MNC上的表現量並無顯著差異，反倒是TLR4與LPS的訊息傳遞協同作用分子sCD14，在SLE病人血清中卻顯著的提高；sTLR2為TLR2免疫反應的調節分子，我們的研究發現SLE病人血清中sTLR2的表現量較正常人低。另外，以anti-TLR2及anti-TLR4抗體來模擬免疫活化刺激PMN與MNC，觀察各項刺激對於sTLR2與sCD14表現的影響；結果顯示，各項刺激能使MNC產生的sCD14減少，sCD14可能參與SLE相關的免疫反應，而sTLR2的產生不受各別刺激影響，推估sTLR2是普遍存在人體血清中的。儘管sTLR2和sCD14在SLE疾病發展所扮演的角色仍有待釐清，希望本實驗結果對於慢性免疫性炎症疾病的發病機制與預防治療能提供一個嶄新的思考策略。 | zh_TW |
| dc.description.abstract | Toll-like receptors (TLRs), a recently discovered family of pattern recognition receptors, play an important role in mediating the activation of innate and adaptive immunity in vertebrate animals. TLRs express on a diverse variety of cells and tissues especially on dendritic cells, macrophages and granulocytes, recognizing pathogens like Gram-positive and -negative bacteria, viral RNA, unmethylated CpG DNA and fungi. Recent studies show that TLRs signaling is involved in either the initiation or the progression of systemic autoimmune disease and chronic inflammatory diseases. Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease and its aetiology remains unclear. In this study, we investigate the expression of TLR2 and TLR4 on polymorphonuclear neutrophil (PMN) and mononuclear cell (MNC) in SLE patients and healthy subjects. We also try to identify the synergistic molecule related to TLR2 or TLR4 signaling and the mechanism involved in the pathogenesis of SLE.
Our results show that the expression of TLR2 or TLR4 on PMN and MNC are not significantly different between healthy subjects and SLE patients. Nevertheless, we detect that the expression level of soluble CD14 (sCD14), the mediator of LPS-TLR4 signaling, in serum are significantly elevated in SLE patients. Moreover, we show that the expression level of soluble TLR2 (sTLR2), the modulator of TLR2 signaling, in serum are reduced in SLE patients. In addition, we utilize anti-TLR2 and anti-TLR4 antibodies to mimic immune stimulations to examine the immune response on PMN and MNC. These findings demonstrate that the production of sTLR2 seems unaffected by those stimulations. Only MNC is down- regulated by those stimulations in sCD14 expression. Likely sTLR2 is an existed molecule in normal serum and sCD14 is related to the immunity in SLE. Although further studies elucidating the detailed mechanisms of sTLR2 and sCD14 are required, this study provides a new direction for SLE treatment and prevention. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T00:05:19Z (GMT). No. of bitstreams: 1 ntu-96-P93448009-1.pdf: 2103180 bytes, checksum: 0b581da3de42cce54133ae5694f57f74 (MD5) Previous issue date: 2007 | en |
| dc.description.tableofcontents | 目 錄
口試委員會審定書..........................................i 誌謝.....................................................ii 英文縮寫及中英文關鍵字..................................iii 中文摘要..................................................1 英文摘要..................................................2 第一章 緒論...............................................3 1.Toll-like受體(TLRs).....................................3 1.1 TLRs的分佈及信號傳導..................................4 1.2 TLRs對適應性免疫的影響................................6 1.3 TLRs與慢性免疫性炎症..................................8 2.全身性紅斑狼瘡(SLE)....................................10 2.1 SLE致病機轉..........................................11 2.2 SLE活動性評估與治療預後..............................11 2.3 TLRs在SLE疾病所扮演之角色............................12 第二章 研究動機..........................................14 第三章 儀器與試藥........................................15 第四章 材料與方法........................................18 第五章 結果..............................................23 第六章 討論..............................................27 第七章 展望..............................................32 參考文獻.................................................33 圖表.....................................................40 圖 表 圖1.TLRs家族成員及其相對應配體...........................41 圖2.以流式細胞儀測定正常人與SLE病人其PMN上TLR2及TLR4的表現.......................................................42 圖3.正常人與SLE病人其PMN上TLR2及TLR4表現之分佈情形.......43 圖4.以流式細胞儀測定正常人與SLE病人其MNC上TLR2及TLR4的表現.......................................................44 圖5.正常人與SLE病人其MNC上TLR2及TLR4表現之分佈情形.......45 圖6.正常人與SLE病人血清中sCD14之表現量...................46 圖7.正常人血清中sTLR2 polypeptide的測定..................47 圖8.正常人與SLE病人血清中sTLR2之表現量...................48 圖9.血清中高濃度sCD14表現的SLE病人其sTLR2之表現情形......49 圖10.免疫細胞經由anti-TLR2/anti-TLR4 Ab刺激後其sCD14表現之變化情形.................................................50 圖11.免疫細胞經由anti-TLR2/anti-TLR4 Ab刺激後其sTLR2表現之變化情形.................................................51 | |
| dc.language.iso | zh-TW | |
| dc.subject | Toll-like受體 | zh_TW |
| dc.subject | 全身性红 | zh_TW |
| dc.subject | 斑狼瘡 | zh_TW |
| dc.subject | 可溶性受體sCD14及sTLR2 | zh_TW |
| dc.subject | 模式辨識受體 | zh_TW |
| dc.subject | sCD14 | en |
| dc.subject | systemic lupus erythematosus | en |
| dc.subject | Toll-like receptor | en |
| dc.subject | PAMPs | en |
| dc.subject | sTLR2 | en |
| dc.title | 紅斑性狼瘡患者多形核嗜中性白血球與單核性細胞表面Toll-like
receptors 2及4的表現及血清中可溶性受體sTLR2及sCD14之研究 | zh_TW |
| dc.title | Studies on the expression of TLR2 and TLR4 on polymorphonuclear neutrophils and mononuclear cells and their soluble receptors, sTLR2 and sCD14, in the serum of patients with systemic lupus erythematosus | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 95-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 蔡長祐,謝松洲 | |
| dc.subject.keyword | Toll-like受體,全身性红,斑狼瘡,可溶性受體sCD14及sTLR2,模式辨識受體, | zh_TW |
| dc.subject.keyword | Toll-like receptor,systemic lupus erythematosus,sCD14,sTLR2,PAMPs, | en |
| dc.relation.page | 51 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2007-07-30 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
| 顯示於系所單位： | 分子醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-96-1.pdf 未授權公開取用 | 2.05 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。